Mark Eisner - Feb 21, 2023 Form 4 Insider Report for FIBROGEN INC (FGEN)

Role
Chief Medical Officer
Signature
/s/ Cecelia Monoarfa-Taime, Attorney-in-fact
Stock symbol
FGEN
Transactions as of
Feb 21, 2023
Transactions value $
$0
Form type
4
Date filed
2/23/2023, 07:38 PM
Previous filing
Dec 2, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FGEN Common Stock Award $0 +32.5K +23.02% $0.00 174K Feb 21, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FGEN Stock Option (Right to Buy) Award $0 +55K $0.00 55K Feb 21, 2023 Common Stock 55K $22.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units (RSUs). Twenty-five percent of the RSUs will vest on March 6, 2024, and the remainder of the RSUs will vest in equal amounts quarterly thereafter for the following three years.
F2 Twenty-five percent of the shares subject to the option will vest on March 1, 2024, and the remainder of the options will vest in equal amounts quarterly thereafter for the following three years.